Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

venetoclax 77Cyclophosphamide 68Cytarabine 59fludarabine 49Azacitidine 45Specimen Handling 36fludarabine phosphate 35Rituximab 34Biopsy 30Methotrexate 28ibrutinib 27Daunorubicin 25Dexamethasone 24Vincristine 23Decitabine 22obinutuzumab 21Etoposide 21acalabrutinib 19Tacrolimus 19Dasatinib 19blinatumomab 18Melphalan 18Prednisone 16Mycophenolic Acid 16Granulocyte Colony-Stimulating Factor 16Busulfan 16Whole-Body Irradiation 15Injections 15Doxorubicin 15pegaspargase 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × incomplete Freund's adjuvant × Other hematologic neoplasm × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡